Ocean ChitoRx

Ocean ChitoRx is an oncology-focused biopharmaceutical subsidiary of Ocean Biomedical, specialized in the development of targeted cancer immunotherapies. The company’s pipeline is built upon the pioneering research of scientific co-founder Dr. Jack A. Elias into Chitinase-3-like protein 1 (CHI3L1), a regulator of tumor growth and immune evasion. Ocean ChitoRx is advancing a portfolio of humanized monoclonal and bispecific antibodies designed to block the CHI3L1 pathway, which is highly expressed in several aggressive cancers. Its lead programs target high-unmet-need indications, including non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). By leveraging its relationship with Brown University and Rhode Island Hospital, the company aims to bridge the gap between academic discovery and clinical-stage drug development.